Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641404 | 1.00 | CRBN (0.63) | CRBNDDB1POLBHRH1LMNA | |
| SCHEMBL30830837 | 0.87 | CRBN (0.65) | CRBNDDB1POLBLMNAMAPT | |
| SCHEMBL25501871 | 0.87 | CRBN (0.65) | CRBNDDB1POLBLMNAMAPT | |
| SCHEMBL31382122 | 0.85 | CRBN (0.50) | CRBNDDB1POLBLMNAMAPT | |
| SCHEMBL26641213 | 0.84 | CRBN (0.67) | CRBNDDB1POLBHRH1 | |
| SCHEMBL31382394 | 0.84 | CRBN (0.58) | CRBNDDB1POLBLMNAMAPT | |
| SCHEMBL30643592 | 0.84 | CRBN (0.67) | CRBNDDB1POLBHRH1 | |
| SCHEMBL31382279 | 0.84 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL25196638 | 0.83 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL30201866 | 0.83 | CRBN (0.50) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | CRBN 104/4885DDB1 321/4885POLB 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.